The goal of the research is to provide a first critical test of the novel scientific idea that a combined diet and exercise intervention may ameliorate shortening of leukocyte telomere length (LTL) in individuals with histories of successfully treated non-metastatic bladder cancer (BC) or colorectal adenoma (CRA) compared to a diet only intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
8
The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
UPMC Shadyside
Pittsburgh, Pennsylvania, United States
Leukocyte telomere length (LTL) at the 6 month assessment (controlling for appropriate covariates)
LTL will be measured in blood samples from participants
Time frame: Blood samples will be collected as part of the 6 month assessment
Leukocyte telomere length (LTL) at the 3 month assessment (controlling for appropriate covariates)
LTL will be measured in blood samples from participants
Time frame: Blood samples will be collected as part of the 3 month assessment
Leukocyte telomere length (LTL) at the 12 month assessment (controlling for appropriate covariates)
LTL will be measured in blood samples from participants
Time frame: Blood samples will be collected as part of the 12 month assessment (as feasible)
Telomerase level at 3 months (controlling for appropriate covariates)
Telomerase will be measured in blood samples from participants
Time frame: Blood samples will be collected as part of the 3 month assessment
Telomerase level at 6 months (controlling for appropriate covariates)
Telomerase will be measured in blood samples from participants
Time frame: Blood samples will be collected as part of the 6 month assessment
Telomerase level at 12 months (controlling for appropriate covariates)
Telomerase will be measured in blood samples from participants
Time frame: Blood samples will be collected as part of the 12 month assessment (as feasible)
8-OHdG level at 3 months (controlling for appropriate covariates)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
8-OHdG will be measured in samples from participants
Time frame: Samples will be collected as part of the 3 month assessment
8-OHdG level at 6 months (controlling for appropriate covariates)
8-OHdG will be measured in samples from participants
Time frame: Samples will be collected as part of the 6 month assessment
Superoxide dismutase 1 (SOD1) at 3 months (controlling for appropriate covariates)
SOD1 will be measured in samples from participants
Time frame: Samples will be collected as part of the 3 month assessment
Superoxide dismutase 1 (SOD1) at 6 months (controlling for appropriate covariates)
SOD1 will be measured in samples from participants
Time frame: Samples will be collected as part of the 6 month assessment
Superoxide dismutase 2 (SOD2) at 3 months (controlling for appropriate covariates)
SOD2 will be measured in samples from participants
Time frame: Samples will be collected as part of the 3 month assessment
Superoxide dismutase 2 (SOD2) at 6 months (controlling for appropriate covariates)
SOD2 will be measured in samples from participants
Time frame: Samples will be collected as part of the 6 month assessment
Glutathione peroxidase (Gpx) at 3 months (controlling for appropriate covariates)
Gpx will be measured in samples from participants
Time frame: Samples will be collected as part of the 3 month assessment
Glutathione peroxidase (Gpx) at 6 months (controlling for appropriate covariates)
Gpx will be measured in samples from participants
Time frame: Samples will be collected as part of the 6 month assessment
Systemic Inflammatory Response (SIR) at 3 months (controlling for appropriate covariates)
SIR will be measured in samples from participants
Time frame: Samples will be collected as part of the 3 month assessment
Systemic Inflammatory Response (SIR) at 6 months (controlling for appropriate covariates)
SIR will be measured in samples from participants
Time frame: Samples will be collected as part of the 6 month assessment